Market Overview

UPDATE: Bank of America Reduces PO to $19 on WuXi PharmaTech on Mixed Outlook

Related WX
WuXi Congratulates TaiMed Biologics On Receiving Orphan Drug Designation For Ibalizumab From U.S. FDA
Foundation Medicine And WuXi PharmaTech Announce Strategic Collaboration To Offer Best-in-Class Comprehensive Genomic Profiling in China

Bank of America reiterated its Buy rating on WuXi PharmaTech (NYSE: WX) but reduced its price objective from $19.50 to $19.

Bank of America commented, "WuXi reported 3Q12 results that again beat our/consensus revenue and nonGAAP EPS by 1.7% and 16%/2.4% and 24%. Management narrowed its FY12 guidance to the upper end of the previous guided range, while expecting modest margin pressure in 2013. We raise our FY12 EPS by 3%, but reduce our FY13 rev/EPS by 2%/3%, and our PO accordingly. Trading at 10x 2013E PE with midteen's growth prospect in 2014E, strong balance sheet and healthy cash flow, we believe the margin pressure is more than reflected in the share price."

WuXi PharmaTech closed at $15.19 on Monday.

Latest Ratings for WX

DateFirmActionFromTo
Oct 2013JefferiesMaintainsBuy
Aug 2013JefferiesMaintainsBuy
May 2013JefferiesMaintainsBuy

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (WX)

Around the Web, We're Loving...

Get Benzinga's Newsletters